Trial Profile
Three years of clinical outcomes of Xience/Promus cobalt-chromium everolimus-eluting stent in patients treated with in-stent restenosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Jun 2017
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery restenosis
- Focus Adverse reactions; Therapeutic Use
- 30 Jun 2017 New trial record